Compare MNKD & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNKD | NRK |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 935.2M |
| IPO Year | 2004 | 2002 |
| Metric | MNKD | NRK |
|---|---|---|
| Price | $4.26 | $10.22 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.69 | N/A |
| AVG Volume (30 Days) | ★ 4.9M | 272.5K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $9.33 |
| 52 Week High | $6.51 | $10.80 |
| Indicator | MNKD | NRK |
|---|---|---|
| Relative Strength Index (RSI) | 57.43 | 34.76 |
| Support Level | $3.74 | $10.19 |
| Resistance Level | $4.55 | $10.24 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 83.12 | 2.04 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.